Acro Biomedical (ACBM) Research & Development (2021 - 2023)

Acro Biomedical has reported Research & Development for 3 years, with the latest figure at $396550.0 in Q3 2023.

• For the quarter ending Q3 2023, Research & Development fell 84.26% year-over-year to $396550.0; the trailing twelve-month figure through Jun 2024 stood at $396550.0 (down 95.8% YoY), and the FY2023 full-year result was $4.8 million, down 52.43% from the prior year.
• Research & Development for Q3 2023 stood at $396550.0, down from $1.9 million in the prior quarter.
• The five-year high for Research & Development was $2.5 million in Q4 2021, with the low at $396550.0 in Q3 2023.
• Average Research & Development over 3 years is $2.0 million, with a median of $2.5 million recorded in 2021.
• Year-over-year, Research & Development jumped 292.69% in 2022 and sank 84.26% in 2023.
• Tracing ACBM's Research & Development over 3 years: stood at $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then slumped by 84.26% to $396550.0 in 2023.
• The last three Research & Development figures came in at $396550.0 (Q3 2023), $1.9 million (Q2 2023), and $2.5 million (Q1 2023), per Business Quant data.

Peer Comparison